Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy
Year: 2015
Type: article
Study design: Observational Study
Abstract: UNLABELLED: Acute myeloid leukemia (AML) is characterized by a high relapse rate that has been attributed to the quiescence of leukemia stem cells (LSC), which renders them resistant to chemotherapy. However, this hypothesis is largely supported by indirect evidence and fails to explain the large differences in relapse rates across AML subtypes. To address this, bone marrow aspirates from 41 AML patients and five healthy donors were analyzed by high-dimensional mass cytometry. All patients displayed immunophenotypic and intracellular signaling abnormalities within CD34(+)CD38(lo) populations, and several karyotype- and genotype-specific surface marker patterns were identified. The immunophenotypic stem and early progenitor cell populations from patients with clinically favorable core-binding factor AML demonstrated a 5-fold higher fraction of cells in S-phase compared with other AML samples. Conversely, LSCs in less clinically favorable FLT3-ITD AML exhibited dramatic reductions in S-phase fraction. Mass cytometry also allowed direct observation of the in vivo effects of cytotoxic chemotherapy. SIGNIFICANCE: The mechanisms underlying differences in relapse rates across AML subtypes are poorly understood. This study suggests that known chemotherapy sensitivities of common AML subsets are mediated by cell-cycle differences among LSCs and provides a basis for using in vivo functional characterization of AML cells to inform therapy selection.
Source: Cancer Discovery
Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Center for Research Resources
Awards: In Vivo Cellular and Molecular Imaging Center@Stanford, Highly multiplexed ion-beam tissue molecular imaging with sub-micron resolution, Systems Approach to Immunity and Inflammation, CyTOF, G1658833210, G1898635787, Modeling the Role of Differentiation in Cancer Progression, Multivariate statistical methods, flow cytometry, and network modeling., G291137109, G3161846315, Mass Cytometry Analysis of Signaling Dysfunction in Duchenne Muscular Dystrophy, Multi-scale Complex Systems Transdisciplinary Analysis of Response to Therapy (MC, Integrating mass cytometric and transcriptomic profiles of solid tumors, Software & Hardware Inference Engines for Automated Determination of Primary Cell, Clinical and Laboratory Studies of Malignant Lymphomas, MicroRNAs as T cell sensitivity Rheostats, NHLBI PROTEOMICS INITIATIVE, (PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers, CyTOF Mass Cytometer, G8343853698, Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro
OpenAlex ID: W2123798150
